No Data
No Data
Buy Recommendation for Leap Therapeutics: Promising Phase 2 Trial Developments and Stable Financial Outlook
Leap Therapeutics | 8-K: Leap Therapeutics Reports Third Quarter 2024 Financial Results
Express News | Leap Therapeutics Q2 2024 GAAP EPS $(0.52) Misses $(0.43) Estimate
Leap Therapeutics: Cash Position Expected to Fund Operations Into 2Q 2026 >LPTX
Express News | Leap Therapeutics Q3 Operating Income USD -17.855 Million
Press Release: Leap Therapeutics Reports Third Quarter 2024 Financial Results